- FreeStyle Libre 2 system continuously measures glucose data every minute with customizable, optional real-time alarms1 to alert users when their glucose is high or low without scanning - Now for ...

ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

The US Food and Drug Administration has cleared the FreeStyle Libre 2 iOS application for use with compatible iPhones. The new app works with the FreeStyle Libre 2 with optional glucose alarms, which ...

Pharmaceutical and med device giant Abbott (NYSE: ABT) said today that it had received approval from the Food and Drug Administration (FDA) for its next-generation integrated continuous glucose ...

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes. The Food and Drug Administration (FDA) has ...

Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out ...

Abbott LaboratoriesABT recently announced the receipt of CE Mark for its next-generation FreeStyle Libre 2 - a continuous glucose monitoring system. This system comes with optional glucose alarms ...

At least seven fires and one injury that were related to some FreeStyle Libre glucose monitor products have led the US Food and Drug Administration to issue a Class I recall, the agency's strongest, ...

The Food and Drug Administration (FDA) has cleared the FreeStyle ® Libre 2 iOS App for use with the FreeStyle Libre 2 14-day glucose sensors in individuals 4 years of age and older with diabetes. The ...